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Abstract 
Purpose. Urolithiasis can impair kidney function. This literature review focuses on the risk of 
kidney impairment in stone formers, the specific conditions associated with this risk and the impact 
of urological surgery. 
Materials and Methods. The PubMed and Embase databases were searched for publications on 
urolithiasis, its treatment, and the risk of chronic kidney disease (CKD), end-stage renal disease 
(ESRD) and nephrectomy in stone formers. 
Results. In general, renal stone formers carry twice the risk of CKD or ESRD, and for female and 
overweight stone formers the risk is even higher. Patients with frequent urinary tract infections, 
struvite stones, urinary malformations and diversions, malabsorptive bowel conditions, and some 
monogenic disorders are at high risk of CKD/ESRD. Shock wave lithotripsy or minimally-invasive 
urological interventions for stones do not adversely affect renal function. Declines in renal function 
generally occur in patients with pre-existing CKD or with a large stone burden requiring repeated 
and/or complex surgery. 
Conclusions. Although the effect size is modest, urolithiasis may cause CKD thus it is mandatory 
to assess patients with renal stones for their risk of developing CKD/ESRD. We suggest that all 
guidelines dealing with renal stone disease should include assessing this risk. 
 
Index words: chronic kidney disease; lithotripsy; nephrectomy; review; uretheroscopy; urolithiasis 
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Introduction 
Urolithiasis is a common condition, with a prevalence of about 9% in the general population.1,2 
Although it is generally considered an unpleasant, but relatively benign condition, urolithiasis can 
impair kidney function as a consequence of: the renal stone per se (obstruction, infection), 
parenchymal damage induced by the primary condition leading to stone formation (some 
monogenic disorders, nephrocalcinosis, secondary hyperoxaluria, etc.), or urological treatments for 
the condition.3 The present literature review was conducted to ascertain the entity of the risk of 
kidney impairment in stone formers, whether specific conditions are associated with this risk (e.g. 
demographics, type of stone, etc.), and the role of urological surgery. We specifically looked for 
evidence addressing the following questions: i) is there a risk of chronic kidney disease (CKD) and 
end-stage renal disease (ESRD) associated with nephrolithiasis? ii) which stone patients are at high 
risk of CKD/ESRD? iii) do urological treatments for stones cause irreversible kidney damage, 
thereby increasing the risk of CKD/ESRD? iv) which factors are associated with a higher risk of 
CKD/ESRD after urological treatments for stones? v) what is the risk of nephrectomy in 
urolithiasis? 
 
Methods 
 
Search strategy 
The terms used to search specialized registries (PubMed, Embase) for the purpose of this analysis 
are listed in the Appendix. The search covered the period from January 1965 up until July 2016; the 
searches were limited to the English language. A few articles were also retrieved from the reference 
lists of review articles and relevant studies. We considered randomized controlled trials as well as 
observational studies. 
 
Data extraction and analysis 
All identified publications were scrutinized for relevance to the study before inclusion, based 
initially on title and abstract, and then by reading the full texts. For all selected articles, data were 
extracted by one reviewer and checked by a second reviewer using a data extraction form that 
included patient characteristics, methodological quality, study characteristics, details of 
interventions, and outcome measures. The GRADE system was used to ascertain the validity of the 
eligible studies and the strength of the evidence. The outcome measures considered were ESRD or 
CKD stages,4 or predetermined levels of glomerular filtration rate (GFR), or serum creatinine. 
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Results 
 
Risk of CKD/ESRD associated with nephrolithiasis 
The literature available on this topic amounted to 399 papers, and 17 of them were considered in the 
present review. Among the 17 studies, only 5 cohort studies assessed the risk of incident 
CKD/ESRD in patients with urolithiasis, and 2 cross-sectional studies estimated the probability of 
CKD associated with a history of renal stones. 
In a prospective open cohort study using data from a primary care population of 1.5 million, two 
scores were developed to estimate the individual 5-year risk of moderate-severe CKD and ESRD. 
Using both scores, a history of renal stones was associated with a risk of developing CKD in 
women.5 The risk of developing a GFR <45 mL/min was 27% higher in female stone formers than 
in women with no history of stones. 
In a registry cohort study, one or more episodes of stones were associated with a higher risk of 
ESRD (adjusted hazard ratio [HR] 2.16, 95% confidence interval [CI] 1.79, 2.62), new-onset CKD 
stage 3b-5 (HR 1.74, 95% CI 1.61, 1.88), and doubling serum creatinine levels (HR 1.94, 95% CI 
1.56, 2.43). The excess risk of adverse outcomes associated with one or more episodes of stones 
was greater in women than in men, and in people <50 years of age. However, the absolute rates of 
adverse renal outcomes associated with stones were modest: the unadjusted rate of ESRD was 2.48 
per million person-days for people with a history of stones versus 0.52 per million person-days for 
the remainder of the population.6 
A registry study on residents of Olmsted County, Minnesota, confirmed that stone formers were at 
higher risk of ESRD after adjusting for diabetes, hypertension, dyslipidemia, gout, and CKD (HR 
2.09, 95% CI 1.45, 3.01). Compared with controls, stone formers who developed ESRD were more 
likely to have a history of hydronephrosis (44% versus 4%), recurrent urinary tract infections (26% 
versus 4%), acquired single kidney (15% versus 3%), neurogenic bladder (12% versus 1%), and 
ileal conduit (9% versus 0%), but not diabetes or hypertension.7 The risk of ESRD attributable to 
urolithiasis - i.e. new cases of ESRD secondary to urolithiasis and its complications or associated 
conditions - was estimated to be only 5.1% of all ESRD cases.  
The Alberta and Olmsted County studies presented very similar estimates of the risk of ESRD in 
stone formers among the general population, identifying an approximately two-fold risk in the 
former vis-à-vis the latter. 
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In a population-based retrospective study of 11,570 participants with incident urolithiasis and 
127,464 without urolithiasis in The Health Improvement Network, the HR for developing CKD 
among the former compared with the latter was 1.82 (95% CI 1.67, 1.98).8 
Among 10,678 participants in the Atherosclerosis Risk in Communities study, the adjusted risk of 
incident CKD was only 10% higher for those with a history of kidney stones and not statistically 
significant; however, the risk was significantly higher among those with plasma uric acid levels ≤6 
mg/dL (HR, 1.34; 95% CI 1.05, 1.72).9 The use of diagnostic codes to define CKD could partially 
explain the overall null findings of this study. 
Among participants in the National Health and Nutrition Examination Survey (NHANES) III with a 
history of kidney stones and a BMI ≥27 kg/m2, the probability of having a GFR <60 mL/min 
compared to a GFR >90 mL/min was 87% higher than in overweight people who were not stone 
formers.10 
In the NHANES 2007-2010 database, a history of kidney stones was associated with CKD, i.e. GFR 
<60 mL/min (odds ratio [OR] 1.76, 95% CI 1.13, 2.76) in women, but not in men, and with dialysis 
(OR 3.26, 95% CI 1.48, 7.16).11 A community-based study in Shanghai, China, found 
nephrolithiasis more prevalent in CKD patients than in non-CKD subjects.(Suppl. Table 1, Ref. 
#13).  
A number of generally poor-quality, often case-control and single-center studies, also support the 
role of renal stones as a risk factor for CKD. In a case-control study on Egyptian hemodialysis 
patients, a history of renal stones emerged as an independent risk factor for ESRD.(Suppl. Table 1, 
Ref. #14) In another case-control study on newly-diagnosed CKD patients, the odds of CKD (based 
on kidney-related ICD-9 discharge diagnoses) among those without hypertension was three times 
higher (95% CI 1.3, 6.8) for patients with versus without kidney stones, after adjusting for all co-
variables.12 
The risk factors for CKD/ESRD in stone formers from studies on the general population are listed 
in Table 1. 
None of these studies distinguished the risk of CKD by phenotype of the underlying disorder 
causing the stone. However renal stones have a different risk of inducing CKD depending on their 
etiology and composition. This was demonstrated by Worcester et al13, who analyzed creatinine 
clearance in over 1,800 patients with urolithiasis. The lowest creatinine clearance values (though 
still not severe enough to be classified as CKD 3 or more) were seen in cystinuria, in uric acid and 
struvite stones, and in overt renal tubular acidosis and intestinal-related nephrolithiasis. In a study 
on 40 cystinuric patients, only 30% had functionally unaffected kidneys with normal GFR and 
bilaterally normal renography.(Suppl. Table 1, Ref. #21) In a larger cohort of 95 cystinuric patients, 
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Assimos et al14 found higher serum creatinine levels and a higher prevalence of nephrectomy than 
in calcium oxalate stone formers. The high prevalence of CKD in cystinuria was confirmed in a 
recently-published French study on 442 cystinuric patients15: 26.7% had CKD (though only 5 
patients had ESRD), and only 22.5% had eGFR >90 mL/min. In these studies on cystinuric stone 
formers, a history of staghorn stones and of multiple open surgical procedures for stone removal 
constituted a relevant risk factor for CKD and nephrectomy. 
In a cross-sectional study on over 1900 patients in which stones were analyzed by infrared 
spectroscopy, patients with struvite and uric acid stones had a lower GFR than those with calcium 
oxalate and phosphate stones.16  
Among patients treated with bariatric surgery techniques, Standard Roux-en-Y gastric bypass and 
malabsorptive procedures are both associated with an increased risk of stones, but only the latter 
raise the risk of CKD as well (adjusted HR 1.96).17 
In patients with primary hyperparathyroidism renal stones were not associated with CKD stage 
3.(Suppl. Table 1, Ref. #6)  
 
Urological treatments and CKD 
Our database search on this topic retrieved 274 papers, and 25 were considered in this review. 
Shock-wave lithotripsy (SWL) and percutaneous nephrolithotomy (PCNL) have been shown to 
damage the renal parenchyma. The amount of tissue irreversibly injured during a single procedure 
is generally very small18, so there is generally an unmeasurable decline in the function of an 
otherwise normal kidney. However, leaving a stone untreated can risk damaging the whole kidney. 
There are numerous caveats to take into account when analyzing the available literature on this 
topic. Baseline renal function is crucially important when investigating renal dysfunction occurring 
after a treatment because the contribution of the small parenchymal loss is dependent on its relative 
contribution to overall renal function. A variety of available urological treatments may have been 
used, alone or in different combinations, in the same patient, and some patients must be treated 
repeatedly for the same stone or for recurrent stones. Unfortunately, only a few articles enable us to 
disentangle these complexities. Any hypertension developing after SWL described in the past19 is 
another aspect to consider because it may well be a sign of renal damage. 
As a general observation, the available evidence on the impact on the GFR of different urological 
techniques for removing stones is of very poor quality, deriving essentially from a number of small 
observational, single-center, retrospective studies. Many of them are flawed for the following 
reasons: 
1. renal function was only assessed in the very short term (<3 months); 
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2. cases with obstructive uropathy and/or complex/staghorn stones were included in the 
sample. In these conditions, it may be difficult to quantify the net impact of factors 
potentially impacting renal functions in opposite directions, e.g. the damage caused by the 
surgical procedureor by the prior obstructive/inflammatory damage, and any improvement 
in renal function after the obstruction was removed; 
3. the methods used to assess renal function were inadequate (i.e. estimated GFR in patients 
with two kidneys); for the specific question addressed here, the most informative studies are 
those concerning patients with single kidneys, or that assess renal function separately in 
each kidney by means of nuclear scanning). 
It is also important for studies on the risk of CKD following SWL to report the specific treatment 
given, i.e. the number of shocks delivered per session, and the number of sessions, which are bound 
to have changed over the course of almost 30 years (the first study retrieved dated from 1988). 
When we considered only the SWL studies published since 1995 and concerning adult patients with 
single kidneys, or whose renal function was assessed with a split nuclear scan, we retrieved three 
reports dealing with a total of 309 kidneys.20–22 No effect of SWL on GFR or blood pressure was 
observed after a follow-up of at least 12 months. Two retrospective studies on a total of 439 patients 
whose bilateral renal stones were treated simultaneously with SWL, found no variation in serum 
creatinine levels over a 12-month follow-up.23,24 In a small prospective study, only 1 of 25 patients 
developed hypertension more than 8 months after SWL.(Suppl. Table 2, Ref. #37) In four studies 
on 231 children, renal scans performed after a follow-up of more than 3 months revealed 
deterioration in renal function in only one kidney.25–28 Very few studies have examined the risk of 
hypertension developing after SWL in children, and appear to rule out this possibility.25,29 
As for ureteroscopic lithotripsy (URSL), one study on single-kidney patients compared URSL with 
SWL and found no differences in terms of subsequent renal function.30 Multiple URSL procedures 
did not alter the long-term GFR in stone-forming patients with CKD stages 2-3(Suppl. Table 2, Ref. 
#59); and the GFR did not change after URSL in 9 patients whose renal function was examined by 
renal scan.(Suppl. Table 2, Ref. #58)  
In a retrospective study, the risk of CKD (serum creatinine higher than 1.4 mg/dL in males, or 1.2 
mg/dL in females) developing in 87 stone formers treated by percutaneous nephrolithotomy 
(PCNL) was much the same after a 19-year follow-up as in historical, unmatched cohorts of patients 
with stones not treated surgically, or treated with SWL, giving the impression that PCNL is at least 
as safe as other procedures.31 In two studies on a total of 243 patients, PCNL caused some 
deterioration in renal function in 9-15% of cases.32,33 This was probably related to multiple 
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punctures and a previously impaired renal function. Similar data emerged from a retrospective study 
on children.(Suppl. Table 2, Ref. #31)  
In a cross-sectional study of 171 patients with severe idiopathic calcium nephrolithiasis, those with 
a GFR <80 mL/min experienced more extensive stone surgery and complications than those whose  
GFR was >80.(Suppl. Table 2, Ref. #24) Similar findings recently emerged from the CROES PCNL 
study of a registry cohort of more than 5,600 patients who underwent PCNL. Patients with CKD 
stages 4-5 were those with a history of PCNL, URSL or nephrostomy; and they had positive urine 
cultures consistent with their higher prevalence of staghorn stones.34  The risk of CKD was also 
associated with the number of stone removal procedures performed, and with a lower stone-free rate 
in single-kidney patients.35 
A retrospective study on SWL-treated stone formers identified a 20% increase in the risk of CKD 
stage 3 for every 1 mm increase in the stone burden up to 20 mm. Oddly enough, this association 
was not seen for greater stone burdens.(Suppl. Table 2, Ref. #23)  
In patients with bilateral obstructive urolithiasis treated with flexible URS or PCNL, the risk of 
CKD stage 5 at 1 year of follow-up was predicted independently by a combination of reduced 
cortical thickness, proteinuria, positive urine culture, and lower preoperative GFR.(Suppl. Table 2, 
Ref. #47) Apart from urinary infection, the other conditions are signs of a CKD existing prior to the 
treatment, and are conditions typically considered when estimating the risk of CKD progression. 
In a recent retrospective study on 2,238 urolithiasis patients with at least one SWL or URS 
procedure, neither SWL nor ureteroscopy was associated with incident CKD.8 
In conclusion, the number and complexity of urological treatments, staghorn stones, stone burden, 
and prior advanced CKD appear to be the most relevant risk factors for severe, chronic renal 
damage after urological treatments for stones. 
 
Risk of nephrectomy in urolithiasis 
We retrieved 2,118 papers from the databases queried on the risk of nephrectomy in patients with 
urolithiasis and 13 of them were considered in this review. In renal stone patients, nephrectomy 
may be due to complications of kidney stones or of urological treatments. Some studies do not 
distinguish between these two situations. No one is certain how often nephrectomy is performed in 
patients with renal stones, nor the reasons for it. 
Among 3,266 prevalent patients attending a large outpatient stone clinic, 3.5% had lost a kidney, 
and the prevalence of kidney loss did not vary over three decades (1970-2003).36 During the years 
2002-2007, nephrectomy was performed in less than 1% of 3,170 children hospitalized for renal 
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stones in the US.37 A study on the trend of treatments for upper urinary tract calculi in the US found 
no significant change in the need for nephrectomy during the period from 1999 to 2009.38  
The reasons for kidney loss in renal stone patients are: obstruction, stone burden, and infection.36 In 
a Chinese study conducted between 2001 and 2010, the risk factors for kidney loss and 
nephrectomy in patients with upper urinary tract stones were: calculus >10 mm, loss to follow-up, 
and poor living standards.39 
Only a few studies have investigated the risk of nephrectomy in specific nephrolithiasis phenotypes. 
Struvite and calcium phosphate stones are more prevalent among single-kidney stone formers36 and, 
as already mentioned, cystinuric patients are at higher risk of nephrectomy than calcium oxalate 
stone formers (14.1% versus 2.9%).14 According to the findings of a case population of 48 
cystinuric stone patients, however, the risk of nephrectomy has decreased since 1990 apparently due 
to the use of minimally-invasive urological procedures.40 
A few single-institution studies have reported on the risk of nephrectomy as a complication of 
PCNL. In the two largest series, involving 1,039 and 568 kidneys undergoing PCNL, only one 
patient in each series (0.1% and 0.2% of the sample, respectively) required urgent nephrectomy for 
severe bleeding.41,42 Other, smaller studies found prevalences of up to 1%.43,44 In a Japanese study 
on 2,129 patients with ureteral stones who underwent URSL between 1985 and 2006, there were 
only 2 cases of nephrectomy being performed for ureteral perforation.45 
 
Taken together, these studies demonstrate that currently-used urological treatments of renal and 
ureteral stones are safe. Although the risk of nephrectomy is low globally and may be decreasing, 
apparently due to modern urological approaches to stone removal, some types of stone (cystine and 
struvite stones) still carry a risk of nephrectomy. A careful patient follow-up is crucial to the 
prevention of such a severe complication. 
 
Discussion 
Renal stone formers have approximately a two-fold higher risk of impaired renal function or need 
for renal replacement therapy than the general population. Female and overweight stone formers are 
at greater risk, together with those who frequently have UTI or struvite stones. Patients with urinary 
malformations and diversions, malabsorptive bowel syndromes, or monogenic disorders that cause 
stones are at particularly high risk of CKD/ESRD. For the rarer forms of kidney stones, an estimate 
of the risk of CKD/ESRD is proposed in Table 2 on the grounds of personal experience, case 
reports, previously-cited studies and very small observational studies.18 While it is difficult to 
separate the relative contribution of mechanical and metabolic factors affecting renal function, it 
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can be hypothesized that some conditions such as cystinuria, renal tubular acidosis and intestinal-
related nephrolithiasis carry a higher risk of kidney damage. 
Although there are no studies of sufficiently good quality available on the effects of non-invasive or 
minimally-invasive urological treatment for stones on renal function, it would seem that whenever 
clinically relevant renal damage is observed, this is due mainly to primary conditions demanding 
repeated and/or complex surgeries. 
Early access to the best urological treatments seems to be indispensable in order to avoid severe 
renal damage, nephrectomy and ESRD. 
 
Conclusions 
Although the effect size is modest, urolithiasis should be seen as a condition that may lead to CKD, 
so it is mandatory to assess renal stone formers in terms of their global risk of developing 
CKD/ESRD. We recommend that all guidelines dealing with renal stone disease include an 
assessment of this risk. 
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Appendix 
 
Search strategy for the section “Risk of CKD/ESRD associated with nephrolithiasis” 
PubMed: 
(urolithiasis[mesh] OR urolithiasis[tiab] OR nephrolithiasis[tiab] OR ((renal[tiab] OR kidney[tiab]) 
AND (stone*[tiab] OR calculi[tiab] OR calculus[tiab]))) 
AND 
(renal insufficiency, chronic[mesh] OR chronic kidney disease[tiab] OR chronic renal 
insufficiency[tiab]) 
AND 
risk[tiab] 
AND 
english[la] 
AND 
"1965/01"[pdat] : "2016/07"[pdat] 
 
Embase: 
('urolithiasis'/exp OR urolithiasis:ab,ti OR nephrolithiasis:ab,ti OR ((renal:ab,ti OR kidney:ab,ti) 
AND (stone*:ab,ti OR calculi:ab,ti OR calculus:ab,ti))) 
AND 
('chronic kidney disease'/exp OR 'chronic kidney disease':ab,ti OR 'chronic renal 
insufficiency':ab,ti) 
AND 
risk:ab,ti 
AND 
english:la 
AND 
[1965-2016]/py 
 
Search strategy for the section “Urological treatments and CKD” 
PubMed: 
(renal insufficiency, chronic[mesh] OR chronic kidney disease[tiab] OR chronic renal 
insufficiency[tiab] OR kidney damage[tiab] OR renal damage[tiab]) 
AND 
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(lithotripsy[mesh] OR lithotripsy[tiab] OR eswl[tiab] OR ureteroscopy[tiab]) 
AND 
english[la] 
AND 
"1965/01"[pdat] : "2016/07"[pdat] 
 
Embase: 
('chronic kidney disease'/exp OR 'chronic kidney disease':ab,ti OR 'chronic renal insufficiency':ab,ti 
OR ‘kidney damage’:ab,ti OR ‘renal damage’:ab,ti) 
AND 
(‘lithotripsy’/exp OR lithotripsy:ab,ti OR eswl:ab,ti OR ureteroscopy:ab,ti) 
AND 
english:la 
AND 
[1965-2016]/py 
 
Search strategy for the section “Risk of nephrectomy in urolithiasis”  
PubMed: 
(urolithiasis[mesh] OR urolithiasis[tiab] OR nephrolithiasis[tiab] OR ((renal[tiab] OR kidney[tiab]) 
AND (stone*[tiab] OR calculi[tiab] OR calculus[tiab]))) 
AND 
(nephrectomy[mesh] OR nephrectomy[tiab] OR single kidney[tiab]) 
AND 
english[la] 
AND 
"1965/01"[pdat] : "2016/07"[pdat] 
 
Embase: 
('urolithiasis'/exp OR urolithiasis:ab,ti OR nephrolithiasis:ab,ti OR ((renal:ab,ti OR kidney:ab,ti) 
AND (stone*:ab,ti OR calculi:ab,ti OR calculus:ab,ti))) 
AND 
(‘nephrectomy’/exp OR nephrectomy:ab,ti OR ‘single kidney’:ab,ti) 
AND 
english:la 
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AND 
[1965-2016]/py  
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Table 1 
 
Risk factors for CKD/ESRD in stone formers from studies on the general population 
Female gender 
Overweight 
Frequent UTI 
Struvite stones 
Acquired single kidney 
Neurogenic bladder 
Previous obstructive nephropathy 
Ileal conduit 
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Table 2 
 
Risk of CKD/ESRD in special forms of nephrolithiasis 
 
Special forms of urolithiasis Risk of CKD/ESRD 
Xanthine stones Possible but low 
Dihydroxyadenine stones Possible but low 
Cystine stones High 
Infection stones High 
Indinavir stones Possible but low 
Distal renal tubular acidosis (complete) High 
Distal renal tubular acidosis (incomplete) Very low 
Primary hyperoxaluria Very high 
Secondary hyperoxaluria (bariatric surgery, 
inflammatory bowel disease, bowel resection, 
malabsorptive syndromes) 
High 
Medullary sponge kidney Possible but low 
Other forms of nephrocalcinosis (often associated 
with genetic hypercalciurias) 
High 
Stones associated with anatomical abnormalities of 
the kidney and urinary tract (horseshoe kidney; 
ureterocele, vesico-ureteral reflux, etc.) and 
neurological bladder 
Intermediate-high 
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Abbreviations 
Chronic kidney disease (CKD), confidence interval (CI), end-stage renal disease (ESRD), 
glomerular filtration rate (GFR), hazard ratio (HR), National Health and Nutrition 
Examination Survey (NHANES), percutaneous nephrolithotomy (PCNL), shock-wave 
lithotripsy (SWL), ureteroscopic lithotripsy (URSL) 
 
